Summary:
«The platform, which seamlessly integrates with electronic medical record (EMR) systems, enables physicians to easily access and order prescription and non-prescription DTx through their e-prescribing workflow and subsequently monitor patient fulfillment, according to the company.»
«A rapidly growing category within digital health, DTx delivers clinical interventions directly to patients via software to treat, manage or prevent a broad spectrum of diseases and disorders, including behavioral health conditions and diabetes. The products, which occasionally require a prescription, can be used as standalone therapies or in combination with other treatments or devices. The digital therapeutics market is projected to grow at a compound annual growth rate of nearly 25% from 2022 to 2030 in the United States.»
«Digital health company Cognoa plans to pilot the program, along with Mahana Therapeutics, a developer of prescription digital therapeutics for chronic health conditions and Videra Health, an AI-assisted video assessment and remote patient monitoring platform. Cognoa is a pediatric behavioral health company developing digital diagnostic and therapeutic products.»
Article written by Heather Landi.
27|07|2022
Source:
Fierce Healthcare